Immune Checkpoint Inhibitor–Associated Myositis

myocarditis myositis I mmune checkpoint inhibitors (ICIs) provide frequent durable responses and improve patient overall survival in numerous cancers. Blocking immune checkpoints (Programmed cell Death 1 [PD-1]/PD-ligand 1 or Cytotoxic T Lymphocyte-Associated Protein 4 [CTLA-4]) to restore antitumor immune response may also break immune tolerance to self-antigens and induce specific immune-related adverse events (irAEs). It is interesting to note that the initial descriptions of ICIassociated myocarditis described 25% of concomitant myositis.